Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | CPT2 | P23786 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1101055 | 0.72 | HMGCR (0.38) | HMGCRCHRM1TBXA2RADRA1ATSHR | |
| SCHEMBL8415864 | 0.67 | — | — | |
| SCHEMBL28480408 | 0.63 | HMGCR (0.35) | HMGCRCHRM1TBXA2RADRA1ATSHR | |
| SCHEMBL29065871 | 0.63 | FFAR3 (0.41) | HMGCRCHRM1TBXA2RADRA1ATSHR | |
| SCHEMBL3420650 | 0.63 | — | — | |
| SCHEMBL632284 | 0.63 | FFAR3 (0.41) | HMGCRCHRM1TBXA2RADRA1ATSHR | |
| SCHEMBL631982 | 0.63 | FFAR3 (0.35) | CYP2D6CYP2C19FFAR3TDP1ALDH1A1 | |
| SCHEMBL6828843 | 0.61 | LMNA (0.40) | TSHRCYP2D6CYP2C19HIF1AFFAR3 | |
| SCHEMBL8529326 | 0.61 | — | — | |
| SCHEMBL9419778 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074135-A2 | SILICON DERIVATIVES FOR PET IMAGING | Bayer Schering Pharma AG (DE) | 2009-07-01 | — | — | EP | claimed |
| US-20090035215-A1 | RADIOFLUORINATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-05 | — | — | US | claimed |
| EP-1970064-A1 | Silicon-derivatives for pet-imaging | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-09-17 | — | — | EP | claimed |
| EP-1911452-A1 | Silicon-derivates for PET-Imaging | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-04-16 | — | — | EP | claimed |
| WO-2008040441-A2 | SILICON DERIVATIVES FOR PET IMAGING | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-04-10 | — | — | WO | claimed |
| EP-1908472-A1 | Silicon derivatives for PET imaging | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-04-09 | — | — | EP | claimed |
| EP-2074135-A2 | SILICON DERIVATIVES FOR PET IMAGING | Bayer Schering Pharma AG (DE) | 2009-07-01 | — | — | EP | disclosed |
| US-20090035215-A1 | RADIOFLUORINATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-05 | — | — | US | disclosed |
| US-20090035215-A1 | RADIOFLUORINATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-05 | — | — | US | disclosed |
| EP-1970064-A1 | Silicon-derivatives for pet-imaging | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-09-17 | — | — | EP | disclosed |
| EP-1911452-A1 | Silicon-derivates for PET-Imaging | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008040441-A2 | SILICON DERIVATIVES FOR PET IMAGING | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-04-10 | — | — | WO | disclosed |
| EP-1908472-A1 | Silicon derivatives for PET imaging | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035215-A1 | RADIOFLUORINATION | AFF2, AFF1, NUTF2 | HMGCR 4158/4885CHRM1 10/4885TBXA2R 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.